93 related articles for article (PubMed ID: 9885382)
21. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
22. BIRC2 amplification in squamous cell carcinomas of the uterine cervix.
Choschzick M; Tabibzada AM; Gieseking F; Woelber L; Jaenicke F; Sauter G; Simon R
Virchows Arch; 2012 Aug; 461(2):123-8. PubMed ID: 22733500
[TBL] [Abstract][Full Text] [Related]
23. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
24. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
25. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.
Langer R; Rauser S; Feith M; Nährig JM; Feuchtinger A; Friess H; Höfler H; Walch A
Mod Pathol; 2011 Jul; 24(7):908-16. PubMed ID: 21516080
[TBL] [Abstract][Full Text] [Related]
26. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
27. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry].
Scheer M; Prange W; Petmecky K; Schirmacher P; Zöller JE; Kübler AC
Mund Kiefer Gesichtschir; 2003 May; 7(3):138-45. PubMed ID: 12764679
[TBL] [Abstract][Full Text] [Related]
29. [Amplification and overexpression of c-erbB2 in human breast cancer].
Chen Y; Dong J; Li C
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):16-9. PubMed ID: 7656779
[TBL] [Abstract][Full Text] [Related]
30. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma.
Freier K; Joos S; Flechtenmacher C; Devens F; Benner A; Bosch FX; Lichter P; Hofele C
Cancer Res; 2003 Mar; 63(6):1179-82. PubMed ID: 12649172
[TBL] [Abstract][Full Text] [Related]
31. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas.
Cho EY; Park K; Do I; Cho J; Kim J; Lee J; Kim S; Kim KM; Sohn TS; Kang WK; Kim S
Mod Pathol; 2013 May; 26(5):677-84. PubMed ID: 23238628
[TBL] [Abstract][Full Text] [Related]
33. Overexpression and gene amplification of both ERBB2 and EGFR in an esophageal squamous cell carcinoma revealed by fluorescence in situ hybridization, multiplex ligation-dependent probe amplification and immunohistochemistry.
Oyama T; Okamoto K; Nakamura R; Tajiri R; Ikeda H; Ninomiya I; Ooi A
Pathol Int; 2015 Nov; 65(11):608-13. PubMed ID: 26314265
[TBL] [Abstract][Full Text] [Related]
34. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
[TBL] [Abstract][Full Text] [Related]
35. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
36. [Amplification and expression of c-erbB2 oncogene in normal, hyperplastic, and malignant endometria].
Lu Y; Czerwenka K; Heuss F
Zhonghua Fu Chan Ke Za Zhi; 1996 Nov; 31(11):656-9. PubMed ID: 9387524
[TBL] [Abstract][Full Text] [Related]
37. The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix.
Chang JL; Tsao YP; Liu DW; Han CP; Lee WH; Chen SL
Gynecol Oncol; 1999 Apr; 73(1):62-71. PubMed ID: 10094882
[TBL] [Abstract][Full Text] [Related]
38. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
39. [Study of the amplification and expression of c-erbB2 oncogene in epithelial ovarian tumors].
Hou Y; Wang M; Liu W
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):426-8. PubMed ID: 9387293
[TBL] [Abstract][Full Text] [Related]
40. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
